Introduction
Epilepsy is one of the most prevalent neurological disorders and generally requires lifetime treatment. For most patients antiepileptic drugs (AEDs) are the mainstay of the management of epilepsy. 1 However in 30% of all epilepsy patients complete seizure
control cannot be achieved despite adequate treatment with AEDs or patients may suffer from unacceptable systemic side effects. 2 These patients with refractory epilepsy provide the impetus for a continuous search for alternative treatment options. One of the underlying causes of refractoriness may be insufficient bioavailability of the AED(s) at the ictal onset region. Patients with refractory epilepsy are often resistant to a broad range of AEDs with different mechanisms of action, suggesting that nonspecific mechanisms are responsible for their limited efficacy. 3 The entrance of drugs into the brain is limited by the blood brain barrier (BBB). There is evidence that impaired drug penetration into the brain may be due to (regional) overexpression of (multi)drug efflux transporters at the site of the BBB. [3] [4] [5] Those transporters recognize a wide range of substrates, including several AEDs. 6 The prototype of these transporters is P-glycoprotein (P-gp). It is hypothesized that there is a constitutive or inherited overexpression of P-gp as a result of a genetic polymorphism 7 or that overexpression may be acquired or induced by some epilepsy-related factors such as uncontrolled seizures. [8] [9] [10] In order to overcome the blood brain barrier -and circumventing multidrug transporters -local delivery of antiepileptic substances directly into the epileptic focus is a tempting and potentially promising strategy. This approach may reduce systemic side effects and allows to deliver larger local doses to obtain seizure control. 11 This is an overview of the currently investigated strategies for local delivery in the brain (Table 1) with special attention to local brain delivery of adenosine for the treatment of epilepsy.
Strategies for local compound delivery in the brain

Intraventricular or intrathecal administration
The BBB can be bypassed by administration of drugs directly into the cerebrospinal fluid (CSF) via compound infusion through intraventricular of intrathecal catheters. Despite the fact that 100% of the administered drug reaches the brain, this administration route has several disadvantages. One major limitation is the nonuniform drug distribution throughout the subarachnoid space with very high local concentrations at the administration site and very low to zero concentrations at a distance. 11, 12 Penetration from the Local delivery of compounds directly into the brain may become an attractive treatment option for several neurological diseases. Higher therapeutic drug levels may be reached at the targeted brain region and in this way systemic side effects avoided. This paper provides an overview of the currently investigated experimental and clinical local delivery strategies in the brain ranging from delivery via pump mechanisms to more advanced techniques with cell and gene therapy. The second part focuses on local brain delivery strategies for epilepsy with special attention to adenosine. Adenosine is a good candidate for local delivery techniques for epilepsy because of its proven anticonvulsive effect and it cannot be given systemically because of systemic side effects. An overview of the current published studies with local delivery of adenosine is given.
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CSF deep into the brain is limited, especially for high molecular weight compounds, but may be enhanced by creating a pressure gradient ('convection', see further). 13 When a drug is injected into the cerebral ventricle, the elimination rate from the central nervous system is dependent on the cerebrospinal fluid dynamics. 12 Injection volume, osmolarity, pH, injection rate, etc. may influence this balance and have an impact on efficacy and safety of this administration route. 14 Other pitfalls with this delivery strategy are difficulties in maintaining access (e.g. catheter problems) and possible neurotoxicity. 11, 15 Direct drug delivery into the CSF is performed in the oncology domain as a form of regional chemotherapy. 11 The most commonly used application consists of continuous intrathecal infusion of baclofen or narcotics via a subcutaneous implanted pump for management of spasticity and pain. Although much experience is available with this technique, there are still possible complications mostly related to pump or catheter malfunction.
16,17
Polymeric controlled release ('wafers')
Biocompatible synthetic polymers, impregnated with a specific compound, may be used as a source for controlled drug release in the brain. Biodegradable polymers release the compound while breaking down, whereas the matrix of non-degradable polymers remains intact after complete release of the drug. Of course the need for removal of the non-degradable polymers limits their use for clinical applications in the brain. The polymers itself are made from various materials and the complex of the polymer and the drug is mostly referred to as a 'wafer'. 18 The pharmacokinetics depend on the polymer and the characteristics of the released compound. Biodegradable polymer wafers with controlled release of carmustine ('Gliadel 1 ' wafers) are approved for clinical use for the treatment of high-grade gliomas. 19 Since the successful development of this wafer, other chemotherapeutic agents are also used or investigated for incorporation into polymers. 20 
Convection-enhanced delivery (CED)
Poor penetration into the brain and limitation of drug dosage at the implant site are disadvantages of the intraventricular/ intrathecal administration and implantation of compoundreleasing wafers as described above. To overcome these problems, the technique of 'convection-enhanced delivery' (CED) has been developed. 13 CED is defined as the infusion of a therapeutic fluid via surgically implanted catheters under positive pressure. By using a syringe pump, continuous positive pressure creates a bulk flow mechanism (i.e. convection). Compared to diffusion alone, a greater distribution volume is achieved. 21, 22 The precise area reached using CED depends on different factors like infusion rate, infusion volume, cannula size and compound characteristics. Especially catheter-related problems with air bubbles and backflow of the solution may interfere with the distribution area and are a challenge for the neurosurgeon. 23 It is not an approved treatment yet, but clinical trials with administration of chemotherapeutics to treat brain tumours using CED have been performed. Nanoscaled particles can also be administered via CED to obtain deep penetration of the nanoparticles into the brain parenchyma. 21 
Carrier vehicles: nanoscaled drug delivery systems
This strategy for drug delivery in the brain makes use of very small ('nano-scaled') carriers which can be administered orally, pass the BBB and release the compound into the brain. Nanoparticles are by definition smaller than 100 nm, but for medical purposes also larger particles (up to 1000 nm) are used. Because of their small size, they can penetrate cell membranes, including the BBB, and may be an ideal source for local drug delivery. The active compound can be adsorbed on the surface, enclosed in the shell or trapped inside its core. 24 Major advantages of this strategy are the improvement of solubility of poorly water-soluble drugs, increase of the half-life of drug systemic circulation with a constant rate of drug delivery at the target zone and the reduction of systemic side effects by delivering at the target place. 25, 26 Although the use of nanoparticles seems a promising strategy, there are definitely some limitations. First, due to their physical properties there is rapid clearance of colloidal nanoparticles from the blood stream and accumulation in the liver or spleen. This may be partially solved by addition of polyethylene glycol to the surface. A second pitfall is toxicity of some nanoscaled drug delivery systems, especially in case of non-degradable particles. 27 More research on the long-term safety of nanoparticles is warranted. Meanwhile some nano-particle based therapies are in the stage of clinical trials, but not targeted to the brain. Studies for brain-delivery are still in the experimental phase. 26 
Cell transplants
Biological substances can be delivered locally in the brain via transplanted cells. In the first experimental and clinical studies, fetal cells were grafted for cell-based delivery of therapeutic compounds. Since the use of fetal cells implies many practical and ethical problems, a lot of research is done to develop a strategy where stem cells are used as a source for local delivery in the brain. [28] [29] [30] [31] Stem cells are pluripotent cells with the ability to divide and renew themselves for indefinite periods ('long-term selfrenewal') and to develop -under the right physiological or experimental conditions -into mature specialized cells, e.g. nerve cells. 32 Different types of stem cells are currently used experimentally for transplantation into the brain: embryonic stem (ES) cells, (adult) neural stem cells or induced pluripotent stem cells. 28, 30 The basic principles for cell transplantation are identical for the different cell sources. Stem cells are isolated, followed by in vitro expansion. If necessary -especially in case of embryonic stem cells -predifferentiation and/or genetic modification may be performed. Stem cells can be engineered to secrete neurotransmitters, neuromodulators or neuropeptides, making them an attractive tool in the treatment of different neurological disorders. Next, stem cells are transplanted in the host where they should survive and provide clinical benefits by local delivery of a therapeutic compound. 30, 33, 34 The overall advantage of using cells for compound delivery is the lack of necessity to refill or replace pumps, polymers or carrier vehicles. A major disadvantage with cell grafting is the lack of control and the fact that only biological compounds can be delivered with this approach.
Gene therapy
Gene therapy is defined as 'the transfer of therapeutic genetic material into cells as a mean to rectify disease'. 35 Using gene 
Local delivery strategies for epilepsy with adenosine
Since epilepsy is a chronic disorder, lifelong treatment may be indicated and chronic local delivery is needed. Use of local delivery therapies with polymers or carrier vehicles are useful for shorttime delivery, e.g. chemotherapeutics for brain tumours, but in epilepsy the most successful strategies may be based on cell or gene therapy, since they do not require replacement or refilling and long-term release is theoretically possible.
Different chronic local delivery strategies have been investigated with various antiepileptic compounds: antiepileptic drugs like valproic acid, 40 phenobarbital and gabapentin, 41 the purine ribonucleoside adenosine, 42-51 the neurotransmitters acetylcholine, 52 GABA, 53-62 norepinephrine [63] [64] [65] [66] [67] [68] [69] and serotonin, 70 and the neuropeptides galanine [71] [72] [73] and neuropeptide Y. [74] [75] [76] [77] Here we focus on local delivery strategies with adenosine based on promising preclinical results. First, some major characteristics of adenosine will be described. Then, an overview of preclinical studies on local delivery of adenosine will be presented (see also in Table 2 ).
Adenosine: physiology and its role in epilepsy
Adenosine is a purine ribonucleoside and plays an important role in many physiological processes, e.g. sleep induction, regulation of the heart rate and blood pressure, regulation of pain perception, neuroprotection and seizure susceptibility. 78 It is an endogenous neuromodulator present in the intra-and extracellular environment of the brain. Adenosine is mainly formed by the breakdown of intra-and extracellular adenine nucleotides via nucleotidases (Fig. 1) . Alternatively adenosine can be produced via hydrolysis of S-adenosyl homocysteine (SAH), but this is an uncommon pathway in the brain. Under normal physiological conditions, the amounts of adenosine in cells and tissue fluids are in the nanomolar range, but in situations of cellular distress -e.g. ischemia or seizuresadenosine levels rapidly increase. Intracellular adenosine triphosphate (ATP)-levels are high (several millimolars) and in case of cell damage ATP is released into the extracellular environment and rapidly transformed to adenosine by ectonucleotidases. The intracellular formation of adenosine increases with increased cellular workload and is related to increased oxygen consumption. 79, 80 The intra-and extracellular adenosine concentrations equilibrate via passive nucleoside transporters. Adenosine is catabolized by adenosine deaminase (ADA) and adenosine kinase (ADK). Especially ADK, that is mainly present in astrocytes in the brain, is important to maintain the levels of adenosine constant and low. 80 Adenosine acts via binding to specific G-protein coupled adenosine receptors: the A 1 , A 2A , A 2B and A 3 receptors. 81 Throughout the nervous system, there is a specific distribution of these receptors. The A 1 and A 2A receptors are most abundant in the brain and are responsible for the majority of the physiological effects. 82 The inhibitory effect of adenosine is mediated by binding to the high-affinity A 1 receptor present in the cerebral cortex, hippocampus, thalamus, cerebellum, brain stem and the spinal cord. This receptor is coupled to an inhibitory G protein (G i ) leading to inhibition of adenylyl cyclase, activation of phospholipase C, increase of conductance of K + channels and inhibition of presynaptic Ca 2+ channels. Activation of presynaptic A 1 receptors results in inhibition of release of excitatory neurotransmitters (glutamate) whereas activation of the postsynaptic A 1 receptors hyperpolarizes neurons. 82, 83 These inhibitory effects play an important role in epilepsy. During an epileptic seizure, extracellu- Table 2 Overview of the studies performed with local delivery of adenosine. Of each study, the source of adenosine release, the implantation site and the animal model is mentioned. The disadvantages of the several strategies are highlighted. The restriction of the use of polymers or pumps is the need for refilling or replacement. This may be solved by the use of transplantation of adenosine-releasing cells directly into the brain. However this is coupled with limited control on cell integration and adenosine release after transplantation. Also long-term effects of cell-based strategies are not known (Ref. = reference). 47 48 Fetal neural progenitor cells Not yet performed 99 100 Gene therapy Not yet performed in vivo lar adenosine concentrations rapidly rise and are believed to play a role in the termination of the seizure via binding to the inhibitory A 1 receptor. During the progression of epilepsy, an increase in ADK levels is observed, in parallel with ongoing astrogliosis often found in epilepsy. Increase of ADK leads to lower ambient levels of adenosine which may contribute to refractory epilepsy. 84 Therefore adenosine administration may be a potential treatment for epilepsy. Since it cannot be given systemically because of its severe side effects such as decreased heart rate, blood pressure and body temperature, local delivery of adenosine may be a promising alternative. 84 
Strategies for local delivery of adenosine in epilepsy
Initial studies with acute administration of adenosine (analogues) into the brain of epileptic animals have proven the seizure suppressive effects of adenosine. [85] [86] [87] [88] [89] As a next step, adenosine was infused chronically in the kindling model and the post-status epilepticus model for temporal lobe epilepsy. In the kindling model, seizures are provoked by repeated administration of short electrical stimuli in limbic brain regions (hippocampus, amygdala). The provoked seizure is visible as the 'afterdischarge': a high amplitude, high frequency discharge on the EEG. The 'seizure severity' refers to the clinical manifestation of the seizure and is scored according to the 5 stages of Racine: stage 1, immobility, eye closure, twitching of vibrissae, facial clonus, wet dog shakes; stage 2: head nodding, chewing, severe facial clonus, wet dog shakes; stage 3: clonus of one forelimb; stage 4: rearing, bilateral forelimb clonus; stage 5: rearing, bilateral forelimb clonus, loss of balance and falling. 90 Seizure severity and afterdischarge duration are important parameters to evaluate therapeutic effect of an experimental treatment in the kindling model. 91, 92 Post-status epilepticus (SE) models are characterized by spontaneous seizures. In these models a SE is evoked by tetanic electrical stimulation of the brain or administration of a chemoconvulsant (kainic acid, pilocarpine). 93 After a latent period, the spontaneous seizures develop typically concomitant with histopathological changes in the hippocampus as seen in patients with refractory temporal lobe epilepsy. These post-SE animal models are considered to resemble more the human epilepsy condition than the kindling model. 94 The first study describing chronic delivery of adenosine in the brain was performed by Boison et al. In this experiment, adenosine was delivered into the lateral ventricle via a synthetic ethylene vinyl acetate copolymer. 42 In vitro the polymers released approximately 20-50 ng adenosine per day. Individual polymers were implanted into the lateral brain ventricles of kindled rats. As long as adenosine was released by the polymers (i.e. 14 days), a sustained reduction of stimulus-induced seizures was found.
Recently, an alternative synthetic drug delivery system based on silk fibroin was developed. 51 The use of silk fibroin has several advantages because it is biocompatible and biodegrades slowly, allowing an increased release time. 95 The adenosine releasing silkbased polymers was implanted into the infrahippocampal fissure of fully kindled rats and naïve rats prior to kindling. These experiments showed a dose-dependent suppression of kindled seizures and a decrease of the kindling rate. The polymers released adenosine for 10 days and this corresponded nicely with the period of seizure suppression. 49, 51 Van Dycke et al. administered adenosine via osmotic minipumps directly into the hippocampi of rats with spontaneous seizures.
Continuous delivery of high doses of adenosine (33 mg per day) resulted in a mean reduction of (both convulsive and nonconvulsive) seizures of 33% compared to the baseline seizure frequency without side effects. 50 In saline-treated control rats seizure frequency further increased with 35% compared to the baseline. The therapeutic effect was completely reversed after stopping local delivery of adenosine. Although results of polymer and pump-based delivery are promising, the disadvantage of these systems is the loss of seizure control after complete compound release. In order to obtain more sustained adenosine release and seizure suppression, cell-based therapies for adenosine were developed. Kidney fibroblasts, 45 mouse myoblasts 44 and mouse embryonic stem cells 43, 96 were genetically engineered in order to release adenosine by disrupting the gene for ADK through chemical mutagenesis or via homologous recombination. Due to the absence of ADK expression, less adenosine is phosphorylated to adenosine monophosphate (AMP) resulting in an intracellular accumulation of adenosine. As a result adenosine is passively secreted by the genetically engineered adenosine kinase knockout (Adk
) cells via the nucleoside transporters (Fig. 1) .
[ ( ) T D $ F I G ] Using this technique cells could be engineered to release 50 ng adenosine per 100,000 cells per 24 h in culture. After encapsulation of adenosine releasing cells in a semi-permeable membrane, capsules were transplanted in the lateral ventricles of fully kindled rats. [43] [44] [45] Transplantation of engineered kidney fibroblasts and myoblasts resulted in an almost complete suppression of kindled seizures up to 14 days after transplantation in fully kindled rats. After 14 days a gradual loss of seizure control was found because of the limited survival of the encapsulated cells. This survival-dependent effect was also obvious in experiments where mouse embryonic stem cell derived glial cells were transplanted into fully kindled rats. Three days after transplantation 90% of the transplanted cells were still present in the host brain with complete seizure suppression in 100% of the animals. Seven days after transplantation however, seizure suppression was lost and viable cells were no longer detectable. In all these studies, seizure suppressing effects were confirmed to be mediated by the paracrine release of adenosine since injection of the A 1 receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropyl-xanthine) abolished the adenosine-induced seizure suppressing effects.
Probably because the adenosine releasing cells were encapsulated in these experiments, survival of the cells -and thus the antiseizure effect -was limited. Transplantation of cells into the brain parenchyma may increase cell survival and adenosine release resulting in prolonged antiseizure effects. 97 Adenosine-releasing embryonic stem cells, predifferentiated towards neural precursor cells prior to transplantation, were grafted intrahippocampally prior to hippocampal kindling. 46 A fraction of the cells survived at least four weeks after transplantation and expressed markers of mature neurons at that time point. Transplantation of adenosine-releasing neural precursor cells induced a decrease of the kindling rate.
In a following experiment, use of a lentiviral system resulted in an up to 80% downregulation of ADK expression in human mesenchymal stem cells (hMSCs), resulting in sustained secretion of adenosine by the hMSCs. 48 Transplantation of these engineered hMSCs in the infrahippocampal fissure of mice suppressed seizure activity and neuronal damage during SE. 48 When these hMSCs were transplanted in the same region one day after the SE, mice developed less spontaneous seizures three weeks after transplantation compared to mice implanted with control cells. 47 Van Dycke et al. isolated Adk À/À neural stem cells from adenosine kinase knockout mice as an alternative potential cell source for local delivery of adenosine. Since Adk À/À mice die within 14 days due to hepatic steatosis, the isolation of adult neural Adk À/ À stem cells was not a possibility. 98 Therefore Adk À/À neural stem cells were isolated from fetuses at embryonic day 14. The amount of adenosine release in stem cell culture medium (i.e. in vitro) was evaluated together with their differentiation potential. 99, 100 We found that, compared with data from the above described studies, the amount of secreted adenosine -both from non-differentiated and differentiated fetal Adk À/À cells -was sufficient to obtain a therapeutic effect in the treatment of refractory epilepsy.
Local delivery via stem/progenitor cell transplantation may become an option to treat refractory patients with epilepsy but further research is needed on long-term results in models with spontaneous seizures. Cells must survive and the secretion of the antiepileptic compound must be stable. It has been demonstrated that the survival rate of grafted cells is inversely correlated with the delay between the kainic acid induced status epilepticus and the transplantation. [101] [102] [103] However there are several ways to enhance cell survival after transplantation, e.g. via supplementation of anti-apoptotic or neurotrophic factors. 104 To monitor in vivo secretion of adenosine after transplantation, in vivo monitoring methods are currently developed for adenosine and other neurotransmitters. 105 Studies with (in vivo) gene therapy have not been performed for adenosine yet, but is could be an interesting option considering the successful studies with gene therapy for galanine [71] [72] [73] and neuropeptide Y.
75,77
Conclusion
Local delivery strategies are an attractive option for treating neurological diseases since systemic side effects may be diminished and higher therapeutic doses may reach the brain. In epilepsy, several studies have shown the antiseizure effect of local adenosine delivery. Local delivery using polymers and pumps are controllable sources, but have the disadvantage of the need for refilling or replacement. Transplantation of adenosine releasing stem/neural progenitor cells can resolve this problem since longterm integration and secretion of adenosine is possible. The pitfall with this strategy is the limited control on cell integration and adenosine release after transplantation. Further studies with evaluation of long-term effects of cell-based therapies are warranted. Furthermore in vivo gene therapy may also be an attractive strategy, but has not been tested in case of adenosine.
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